Dos Santos Nascimento Igor José, de Aquino Thiago Mendonça, da Silva-Júnior Edeildo Ferreira
Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceio, Brazil.
Curr Top Med Chem. 2021;21(21):1871-1899. doi: 10.2174/1568026621666210331152702.
Neglected tropical diseases (NTDs) are a group of approximately 20 diseases that affect part of the population in Sub- and Tropical countries. In the past, pharmaceutical industries and governmental agencies have invested in the control, elimination and eradication of such diseases. Among these diseases, Chagas disease (CD) and Human African trypanosomiasis (HAT) are a public health problem, mainly in the countries from the American continent and sub-Saharan African. In this context, the search for new therapeutic alternatives against such diseases has been growing in recent years, presenting cysteine proteases as the main strategy to discover new anti-trypanosomal drugs. Thus, cruzain and rhodesain enzymes are targets widely studied, since the cruzain is present in all stages of the parasite's life, related to the stages of proliferation and differentiation and infection of macrophages; while the rhodesain is related to the immune defense process. In addition, knowledge about the amino acid sequences and availability of X-ray complexes have stimulated the drug searching against these targets, mainly through molecular modeling studies. Thus, this review manuscript will be addressed to cruzain and rhodesain inhibitors developed in the last 10 years, which could provide basis for new lead compounds in the discovery of new trypanocidal drugs. We found 117 studies involving inhibitors of cruzain and rhodesain, being thiosemicarbazones, semicarbazones, N-acylhydrazones, thiazoles-hydrazone, thiazolidinones-hydrazones, oxadiazoles, triazoles, triazines, imidazoles, peptidomimetic, and others. All references were obtained using "cruzain" or "rhodesain" and "inhibitor" as keywords in Science Direct, Bentham Science, PubMed, Espacenet, Springer, ACS Publisher, Wiley, Taylor and Francis, and MDPI (Multidisciplinary Digital Publishing Institute) databases. Finally, we highlighted all these chemical classes of molecules to provide valuable information that could be used to design new inhibitors against Chagas disease and sleeping sickness in the future.
被忽视的热带病(NTDs)是一组约20种疾病,影响着亚热带国家的部分人口。过去,制药行业和政府机构已投入力量控制、消除和根除这些疾病。在这些疾病中,恰加斯病(CD)和人类非洲锥虫病(HAT)是公共卫生问题,主要存在于美洲大陆和撒哈拉以南非洲的国家。在此背景下,近年来针对这些疾病寻找新治疗方法的研究不断增加,将半胱氨酸蛋白酶作为发现新型抗锥虫药物的主要策略。因此,克氏锥虫蛋白酶和罗德西亚锥虫蛋白酶是被广泛研究的靶点,因为克氏锥虫蛋白酶存在于寄生虫生命周期的所有阶段,与增殖、分化以及巨噬细胞感染阶段相关;而罗德西亚锥虫蛋白酶与免疫防御过程有关。此外,关于氨基酸序列和X射线复合物可用性的知识推动了针对这些靶点的药物搜索,主要通过分子建模研究。因此,本综述将探讨过去10年开发的克氏锥虫蛋白酶和罗德西亚锥虫蛋白酶抑制剂,这可为发现新型杀锥虫药物的新先导化合物提供依据。我们发现了117项涉及克氏锥虫蛋白酶和罗德西亚锥虫蛋白酶抑制剂的研究,这些抑制剂包括硫代氨基脲、氨基脲、N-酰基腙、噻唑-腙、噻唑烷酮-腙、恶二唑、三唑、三嗪、咪唑、拟肽等。所有参考文献均通过在科学Direct、本特姆科学、PubMed、欧洲专利局专利数据库、施普林格、美国化学会出版社、威利、泰勒与弗朗西斯以及MDPI(多学科数字出版研究所)数据库中使用“克氏锥虫蛋白酶”或“罗德西亚锥虫蛋白酶”以及“抑制剂”作为关键词获得。最后,我们强调了所有这些分子化学类别,以提供有价值的信息,可用于未来设计针对恰加斯病和昏睡病的新型抑制剂。